Array Technologies, Inc. (NASDAQ:ARRY)

WEB NEWS

Tuesday, July 7, 2015

Research
Array is initiating a 12-patient proof-of-concept study of ARRY-797 in patients with LMNA-related dilated cardiomyopathy (DCM), a serious, genetic cardiovascular disease, believed to be caused by a mutation of the lamin A/C gene which leads to cardiac cell death and heart failure.  This study was designed following discussion with the Food and Drug Administration (FDA) and will be run in connection with leading cardiovascular research centers, including Meriter Wisconsin Heart (affiliate of the University of Wisconsin), University of Colorado, Johns Hopkins University and Brigham and Women's Hospital.  Preliminary results from this trial are expected late this year. "Currently, there are no effective specific treatment options to alter the course of this rare degenerative genetic disease," said Calum A. MacRae, MBCHB, Ph.D. Clinical Director of Genomic Medicine Program and Associate Physician at Brigham and Women's Hospital, Division of Cardiovascular Medicine and Associate Professor of Medicine at Harvard Medical School.  "Based on existing data, I am excited by the potential ARRY-797 holds for these patients." - See more at: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1896599&highlight=#sthash.c5sMHegH.dpuf


Market Data powered by QuoteMedia. Terms of Use